Last reviewed · How we verify
PLATELETS
Platelets, a marketed drug, holds a significant position in its therapeutic area, though specific revenue figures and primary indications are not provided. The key strength of Platelets lies in its mechanism of interacting with specific biological targets to produce a therapeutic effect, which is underpinned by a key composition patent expiring in 2028. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | PLATELETS |
|---|---|
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Body's Affect on Vitamin C (PHASE1)
- Surgical Treatment of Peri-implantitis With Adjunctive Application of Platelet Rich Fibrin (PRF) (NA)
- Platelet Volunteers, Longitudinal and Multi-omic Study
- Clinical Comparison of Alb-PRF vs PRF on Postoperative Morbidity Following FGG Harvesting (NA)
- Longitudinal Studies of Patient With FPDMM
- PRP as Adjuvant Treatment to CTR for Severe CTS Tunnel Syndrome (NA)
- Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion (NA)
- Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PLATELETS CI brief — competitive landscape report
- PLATELETS updates RSS · CI watch RSS